SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Sarepta Therapeutics, Inc. - SRPT

Jan 15, 2016, 11:02 ET from Pomerantz LLP

NEW YORK, Jan. 15, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT).  Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 9980.

The investigation concerns whether Sarepta and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On January 15, 2016, pre-market, the U.S. Food and Drug Administration released a statement by an agency advisory committee that cast significant doubt on the approval prospects of Sarepta's muscular dystrophy drug eteplirsen.  The agency's internal review of eteplirsen stated, in part, that "[a]lthough FDA is prepared to be flexible with respect to a devastating illness with no treatment options, we cannot approve drugs for which substantial evidence of effectiveness has not been established." 

On this news, Sarepta stock has fallen as much as $18.83, or nearly 60%, to $12.80 during intraday trading on January 15, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

CONTACT: Robert S. Willoughby Pomerantz LLP


SOURCE Pomerantz LLP